Category Archives: Myocardial Infarction

Pfizer Myocardial Infarction Treatment Sales Market Competitive Landscape & Company Profiles Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Myocardial Infarction Treatment Sales market. Segmental Analysis Both developed and emerging regions are deeply studied by the authors of the report. Continue reading →

Heart attacks are serious medical emergencies that require immediate attention from a doctor. You could be at risk of a deadly heart attack - or myocardial infarction - if you find that your gums are bleeding without any obvious reason, it's been revealed. Heart attacks are caused by a lack of blood reaching the heart Continue reading →

New Jersey, United States,- A detailed research study on Myocardial Infarction Drug Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Continue reading →

Dr Tushau Prasad, Emergency Physician, Wockhardt Hospital, Mumbai, shares his insights on the immense need of Emergency Medicine (EM) in India in view of the changing burden of diseases Primary prevention measures and vertical programmes are essential in managing burdens of both, communicable and non-communicable diseases, but they do not offer the entire solution. For a significant population, particularly the vulnerable age groups and people with limited access to healthcare, their first encounter with the healthcare system is during an acute illness or injury and many a time, life-threatening too. For these patients, emergency medical services and expertise provides life- and limb-saving interventions during the acute event, while also serving as a gateway to secondary care and an initial contact point for implementing primary prevention strategies and policies Continue reading →

Los Angeles, United State: QY Research recently published a research report titled, Global Eptifibatide Market Research Report 2020-2026. The research report attempts to give a holistic overview of the Eptifibatide market by keeping the information simple, relevant, accurate, and to the point Continue reading →

Antihypertensive Industry studies a class of drugs that are used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Get Sample Copy of this Report @ https://www.orianresearch.com/request-sample/662948 Continue reading →

The Office of Technology Management helps take great ideas at Washington University and bring them to market where they impact your health, patient care and well being for the better. Illustration by Alex Eben Meyer, BFA '98 The Office of Technology Management helps move ideas out of the lab and into the marketplace Continue reading →

The globalIschemic Heart Disease Drugs Marketresearch report provides comprehensive analysis and insights on the overall market size, growth rates, current, and future trends, competitive landscape, segments, and sub-segments analysis and regional and country wise shares. This research report aids the stakeholders in gauging the global Ischemic Heart Disease Drugs industry and deciding the apt strategic moves to be adopted Continue reading →

Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes Key secondary composite first and total MACE reductions of 30% and 29%, respectively, shown with VASCEPA in prespecified tertiary and post hoc exploratory subgroup analyses Reductions also observed in post hoc exploratory analyses of other composite endpoints, in people with diabetes, and in people with established cardiovascular disease with or without diabetes at baseline DUBLIN, Ireland and BRIDGEWATER, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT® study presented during the 80th Scientific Sessions of the American Diabetes Association by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, showed that administration of 4 g/day of VASCEPA® (icosapent ethyl) resulted in significant 23% reductions in both first and total primary composite major adverse cardiovascular events (5-point MACE) in people with diabetes. Reductions of 30% and 29% were observed in both first and total hard (3-point) MACE, the key secondary composite endpoint, respectively Continue reading →

A 39-year-old New Orleans woman whose boyfriend blamed coronavirus for her untimely death, in a social media post that spread nationally in the fearful early days of the pandemics spread across the U.S., in fact died naturally of a weakened heart, a coroners official said Wednesday. The cause of Natasha Otts death on March 20 is listed as dilated cardiomyopathy with remote myocardial infarct, Orleans Parish Coroner Dr Continue reading →